TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00271739

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Telemedicine Unit (HTU)
Description: This study involves the deployment of a home telemedicine unit (HTU). The HTU provides 3 critical functions for patients: videoconferencing, access to information resources and e-mail through a web-enabled workstation, and medical data acquisition through an electronic device interface. The HTUs also included a glucometer and a blood pressure cuff interfaced directly with the HTU.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: usual care
Description: usual diabetes care, as provided by primary care providers
Study: NCT02224066

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor 90 mg twice per day during three months following TAVI

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin 100 mg plus Clopidogrel 75 mg daily during three months following TAVI
Study: NCT02669524

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: IIGI
Study: NCT00684567

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Radiotherapy will be administered in combination with temozolomide during the concomitant radiotherapy phase. Radiotherapy will consist of a conventionally fractioned regimen, delivering a total dose of 60 Gy in 6 weeks, in a once daily schedule of 2 Gy per fraction, for a total of 30 fractions. Radiation will be provided by a linear accelerator of x ray energy of 4 MV or higher.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: During the concomitant radiotherapy phase (6 weeks), temozolomide will be administered in combination with radiotherapy, once daily at 75 mg/m2/day. Then, during the monotherapy phase, subjects will receive 6 cycles of temozolomide alone. Each cycle will last 28 days, and temozolomide will be administered once daily from Day 1 to Day 5 of each cycle. The dose of temozolomide in the first cycle will be 150 mg/m2/day, and may be increased to 200 mg/m2/day for Cycle 2 and subsequent cycles depending on nonhematologic toxicity observed and neutrophil and platelet count values. Capsules containing 5 mg, 20 mg, or 100 mg of temozolomide will be combined to achieve each subject's calculated dose.
Study: NCT03991442

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fimasartan/Amlodipine
Description: Active Comparator: a fixed dose combination of Fimasartan/Amlodipine or placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fimasartan/Amlodipine
Description: Active Comparator: a fixed dose combination of Fimasartan/Amlodipine or placebo
Study: NCT02201459

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nilotinib (Tasigna ®), capsules of 150 mg
Description: Nilotinib 2 capsules of 150 mg orally twice daily at 12 hours difference, fasting (minimum 1 hour before or 2 hours after a meal) for at least 36 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nilotinib (Tasigna ®), capsules of 150 mg
Description: Nilotinib 2 capsules of 150 mg orally twice daily at 12 hours difference, fasting (minimum 1 hour before or 2 hours after a meal) for at least 36 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nilotinib (Tasigna ®) and Pegylated interferon alfa 2a (Pegasys®)
Description: * Nilotinib 2 capsules of 150 mg orally twice daily at 12 hours difference, fasting (minimum 1 hour before or 2 hours after a meal) for at least 36 months and~* Pegylated interferon alfa 2a subcutaneously once a week (auto-injection syringes of 135 and 90 micrograms) at 30 micrograms/week the first month alone (= priming procedure), then at 30 micrograms/2weeks the first month of combination to nilotinib and then at 45 micrograms/week thereafter until month 24 after nilotinib initiation.
Study: NCT04424849

Intervention type: DIAGNOSTIC_TEST
Intervention: CT-Scan
Description: Chest CT scan on admission to the intensive care unit
Study: NCT02656082

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etanercept
Description: Treatment with etanercept is intended for remission induction of DLE only and not for maintenance purpose.
Study: NCT00388934

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Drug eluting stent
Description: percutaneous intervention with implantation of drug eluting coronary stent

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Drug eluting stent
Description: percutaneous intervention with implantation of drug eluting coronary stent
Study: NCT01202877

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-azacytidine
Description: Starting dose: 75 mg/m2/d subcutaneously (SQ) or by vein (IV) on days 1-7 of a 28 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PKC412
Description: Starting dose: 50 mg by mouth twice daily for 14 days (days 8-21), of every 28 day cycle. Starting with cycle 2, PKC412 administered continuously (daily).
Study: NCT04142242

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Meningococcal Polysaccharide (serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine
Description: Pharmaceutical form: Solution for injection; Route of administration: Intramuscular

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Meningococcal Polysaccharide (serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine
Description: Pharmaceutical form: Solution for injection; Route of administration: Intramuscular

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Meningococcal Polysaccharide (serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine
Description: Pharmaceutical form: Solution for injection; Route of administration: Intramuscular

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Meningococcal Polysaccharide (serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine
Description: Pharmaceutical form: Solution for injection; Route of administration: Intramuscular

Intervention type: OTHER
Group type: OTHER
Intervention: Blood sample
Description: Blood sample for assessment of antibody persistence.

Intervention type: OTHER
Group type: OTHER
Intervention: Blood sample
Description: Blood sample for assessment of antibody persistence.
Study: NCT02669524

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: IIGI

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: IIGI

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: IIGI

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standardised liquid meal

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Standardised liquid meal

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standardised liquid meal
Study: NCT02249221

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Quadrivalent cell-culture based influenza vaccin
Description: GC3106, 0.5ml, intramuscular, a single dosing at Day 1

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Trivalent influenza vaccine
Description: GC Flu Pre-filled Syringe Inj., 0.5ml, intramuscular, a single dosing at Day 1
Study: NCT03050034

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: WIN @ Hospital system
Description: WIN @ Hospital system is a wearable and wireless system (Medical Class IIA) that allows continuous and real-time vital signs monitoring, automatically calculating the NEWS score with a personalized alert system for the patient. It does not require the continuous presence of the nurse in front of the control room, but is working with alert on portable devices (ipad).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional monitoring
Description: Vital signs control performed by nurse staff each 6 hours or more, according to medical advice.
Study: NCT03857672

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hypnotic Cognitive Therapy (HYPNOCT)
Description: The HYPNOCT intervention will use hypnotic strategies and suggestions for identifying adaptive cognitions and for making adaptive changes in cognitions more integrated into the participant's belief system (note that traditional CT uses purposeful argument and logic to make these changes; in this condition the investigators add a hypnotic automaticity to this process). Thus, HYPNOCT is a hybrid intervention (more than the sum of CT and hypnosis) that overlaps with both hypnosis and CT. The participant will relax in a comfortable position and listen to the clinician speak. However, unlike standard hypnosis for pain, the post-induction suggestions will focus on changes in cognitive content and processes (as opposed to changes in sensory experience).
Study: NCT01702779

Intervention type: OTHER
Group type: OTHER
Intervention: mechanical ventilation
Description: Prospective, randomized clinical multicentric study in ICU (Intensive Care University)during weaning from mechanical ventilation.

Intervention type: OTHER
Group type: OTHER
Intervention: mechanical ventilation
Description: Prospective, randomized clinical multicentric study in ICU (Intensive Care University)during weaning from mechanical ventilation.
Study: NCT01205841

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ottawa Ankle and Foot Rules
Description: As previously published

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ottawa Ankle and Foot Rules
Description: As previously published

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Buffalo Rule
Description: As previously published

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Buffalo Rule
Description: As previously published

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ottawa Ankle and Foot Rules + application of a tuning fork to the distal fibula and tibia
Description: As previously published

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ottawa Ankle and Foot Rules + application of a tuning fork to the distal fibula and tibia
Description: As previously published

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Thompson Test
Description: As previously published

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Thompson Test
Description: As previously published
Study: NCT02918266

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Scopolamine Placebo
Description: Scopolamine placebo-matching subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Scopolamine Placebo
Description: Scopolamine placebo-matching subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Scopolamine Placebo
Description: Scopolamine placebo-matching subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Scopolamine Placebo
Description: Scopolamine placebo-matching subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Scopolamine Placebo
Description: Scopolamine placebo-matching subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Scopolamine Placebo
Description: Scopolamine placebo-matching subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Scopolamine Placebo
Description: Scopolamine placebo-matching subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Scopolamine Placebo
Description: Scopolamine placebo-matching subcutaneous injection
Study: NCT03014635

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Botulinum Toxins, Type A
Description: Intramuscular injection
Study: NCT02918266

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Scopolamine Placebo
Description: Scopolamine placebo-matching subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Scopolamine Placebo
Description: Scopolamine placebo-matching subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-071 Placebo
Description: TAK-071 placebo-matching DIC
Study: NCT03014635

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Intramuscular injection
Study: NCT00107575

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard treatment plus brief alcohol intervention
Description: Standard smoking cessation treatment with nicotine patch plus a brief alcohol-focused intervention
Study: NCT02918266

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-071 Placebo
Description: TAK-071 placebo-matching DIC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-071 Placebo
Description: TAK-071 placebo-matching DIC
Study: NCT01205841

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Palpation of the fibula
Description: Palpation of the fibula over its entire length.
Study: NCT02918266

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-071 Placebo
Description: TAK-071 placebo-matching DIC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-071 Placebo
Description: TAK-071 placebo-matching DIC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-071 Placebo
Description: TAK-071 placebo-matching DIC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-071 Placebo
Description: TAK-071 placebo-matching DIC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-071 Placebo
Description: TAK-071 placebo-matching DIC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-071 Placebo
Description: TAK-071 placebo-matching DIC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-071 Placebo
Description: TAK-071 placebo-matching DIC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donepezil Placebo
Description: Donepezil placebo-matching over-encapsulated tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donepezil Placebo
Description: Donepezil placebo-matching over-encapsulated tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donepezil Placebo
Description: Donepezil placebo-matching over-encapsulated tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donepezil Placebo
Description: Donepezil placebo-matching over-encapsulated tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donepezil Placebo
Description: Donepezil placebo-matching over-encapsulated tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donepezil Placebo
Description: Donepezil placebo-matching over-encapsulated tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donepezil Placebo
Description: Donepezil placebo-matching over-encapsulated tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donepezil Placebo
Description: Donepezil placebo-matching over-encapsulated tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donepezil Placebo
Description: Donepezil placebo-matching over-encapsulated tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donepezil Placebo
Description: Donepezil placebo-matching over-encapsulated tablet
Study: NCT02389816

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vortioxetine
Description: Vortioxetine tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vortioxetine
Description: Vortioxetine tablets
Study: NCT01000194

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High fat meal
Description: A high fat milkshake containing 55g of fat

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High fat meal
Description: A high fat milkshake containing 55g of fat

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High fat meal
Description: A high fat milkshake containing 55g of fat
Study: NCT00791440

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive-Behavior Therapy
Description: Weekly individual Cognitive-Behavior Therapy (CBT) to target hallucinations and delusions in addition to standard psychiatric treatment.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Psychiatric Treatment
Description: Standard psychiatric treatment.
Study: NCT06163456

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Acute submaximal exercise
Description: 30 min of treadmill running at 70% of the participants maximal oxygen consumption

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acute submaximal exercise
Description: 30 min of treadmill running at 70% of the participants maximal oxygen consumption

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Acute submaximal exercise
Description: 30 min of treadmill running at 70% of the participants maximal oxygen consumption
Study: NCT06023173

Intervention type: DIAGNOSTIC_TEST
Intervention: Deep radiomics-based fusion model
Description: This multi-modal deep radiomics model, using PET/CT, clinical and histopathological data, was able to identify patients with bevacizumab-sensitive CRLM, providing a favorable approach for precise patient treatment.

Intervention type: DIAGNOSTIC_TEST
Intervention: Deep radiomics-based fusion model
Description: This multi-modal deep radiomics model, using PET/CT, clinical and histopathological data, was able to identify patients with bevacizumab-sensitive CRLM, providing a favorable approach for precise patient treatment.

Intervention type: DIAGNOSTIC_TEST
Intervention: Deep radiomics-based fusion model
Description: This multi-modal deep radiomics model, using PET/CT, clinical and histopathological data, was able to identify patients with bevacizumab-sensitive CRLM, providing a favorable approach for precise patient treatment.
Study: NCT01205841

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Palpation of the fibula
Description: Palpation of the fibula over its entire length.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ottawa Ankle and Foot Rules + palpation of the cuboid bone
Description: As previously published

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ottawa Ankle and Foot Rules + palpation over the deltoid ligament
Description: As previously published

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Malleolar Zone Algorithm
Description: As previously published

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Low Risk Exam
Description: As previously published

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bernese Ankle Rules
Description: As previously published

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bernese Ankle Rules
Description: As previously published

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ottawa Ankle and Foot Rules + swelling of the distal fibula
Description: As previously published
Study: NCT04651322

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: upper robot Robot assisted upper arm training(RAT)
Description: The training group received an additional upper robot Robot assisted upper arm training(RAT) with Armeopower® 5 times per week for 4weeks.~\*Robot Assisted Arm training + Conventional occupational therapy

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Conventional therapy
Description: The control group received the usual conventional therapy \*Only Conventional occupational therapy
Study: NCT06023173

Intervention type: DIAGNOSTIC_TEST
Intervention: Deep radiomics-based fusion model
Description: This multi-modal deep radiomics model, using PET/CT, clinical and histopathological data, was able to identify patients with bevacizumab-sensitive CRLM, providing a favorable approach for precise patient treatment.
Study: NCT02814968

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 18-FDG PET/CT

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Whole body MRI

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bone scan
Study: NCT05520814

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-1 inhibitors
Description: treprizumab injection 240mg / carrilizumab injection 200mg / Tirelizumab injection 200mg \* q21d (until the disease progresses, intolerable toxicity or the investigator / subject decides to withdraw from the study, and the duration of PD-1 inhibitor is not more than 96 weeks)

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: chemoradiotherapy
Description: Chemotherapy：~1. GP: gemcitabine 1g/m2 D1, 8 Cisplatin 80 mg/m2 d1~   \* Treatment courses every 3 weeks~2. Cisplatin 80mg/m2 d1 or carboplatin area under the curve 5mg/ml/min \* Treatment courses every 3 weeks~Radiotherapy： All the metastatic lesions received radiation dose from 30 to 60Gy according to different metastatic sites.
Study: NCT02778750

Intervention type: PROCEDURE
Intervention: Two-Bronchoscope Technique
Description: Used to validate the use of sputum to sample the lower airway microbiome
Study: NCT02669524

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Standardised liquid meal
Study: NCT01182116

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: J Pouch
Description: Comparing J pouch, side to end coloanal surgery
Study: NCT00837499

Intervention type: BEHAVIORAL
Intervention: Questionnaire
Description: Interview and survey during visit or by phone, 30 - 40 minutes.

Intervention type: BEHAVIORAL
Intervention: Questionnaire
Description: Interview and survey during visit or by phone, 30 - 40 minutes.
Study: NCT04326673

Intervention type: OTHER
Intervention: Testosterone Measurements in healthy volunteers after fasting
Description: salivary testosterone measurements taken in morning and evening and a single blood test for testosterone taken

Intervention type: OTHER
Intervention: Testosterone Measurements after glucose loading
Description: salivary tstosterone and blood testosterone measurements
Study: NCT02893358

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Allisartan Isoproxil
Description: Allisartan Isoproxil 80mg once daily taken in the morning during 8:00-9:00. To achieve the target blood pressure allisartan isoproxil may be doubled to 160mg once a day. If necessary, amlodipine 2.5mg may be combined with allisartan isoproxil. Duration: 12 months.
Study: NCT00837499

Intervention type: BEHAVIORAL
Intervention: Questionnaire
Description: Interview and survey during visit or by phone, 30 - 40 minutes.